Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia

Molecular Psychiatry

Volumn 15, Issue 9, 2010, Pages 938-953

  Yao, J K ^a,b,c   Dougherty Jr , G G ^a,b   Reddy, R D ^a,b   Keshavan, M S ^b,d,e   Montrose, D M ^b   Matson, W R ^a   Rozen, S ^f   Krishnan, R R ^g   McEvoy, J ^g   Kaddurah Daouk, R ^g  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

5 hydroxyindoleacetic acid; first episode neuroleptic naive; N acetylserotonin; schizophrenia; targeted metabolomics; Trp

Indexed keywords

3 HYDROXYANTHRANILIC ACID; 3 HYDROXYKYNURENINE; 5 HYDROXYINDOLEACETIC ACID; 5 HYDROXYTRYPTOPHAN; ANTHRANILIC ACID; ARIPIPRAZOLE; HALOPERIDOL; KYNURENINE; MELATONIN; N ACETYLSEROTONIN; N METHYLSEROTONIN; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN N ACETYLTRANSFERASE; TRYPTAMINE; TRYPTOPHAN; TRYPTOPHOL;

ADULT; ARTICLE; CHEMICAL INTERACTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; METABOLITE; METABOLOMICS; PRIORITY JOURNAL; SCHIZOPHRENIA; SEROTONIN METABOLISM;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; HYDROXYINDOLEACETIC ACID; KYNURENINE; MALE; MELATONIN; OXIDATIVE STRESS; SCHIZOPHRENIA; SEROTONIN; TRYPTOPHAN; YOUNG ADULT;

EID: 77956439232     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2009.33     Document Type: Article

References (94)

1. Lieberman JA, Koreen AR. Neurochemistry and neuroendocrino-logy of schizophrenia, a selective review. Schizophr Bull 1993; 19: 371-429.
2. Skosnik PD, Yao JK. From phospholipid and fatty acid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia? Prostagland Leukot Essent Fatty Acids 2003; 69: 367-384.
3. Yao JK, Van Kammen DP. Membrane phospholipids and cytokine interaction in schizophrenia. Int Rev Neurobiol 2004; 59: 297-326.
4. Javitt DC, Laruelle M. Neurochemical theories. In: Lieberman JA, Stroup TS, Perkins DO (eds). Text Book of Schizophrenia. American Psychiatric Publishing: Washington, DC, 2006, pp 85-116.
5. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, 'Just the facts': what we know in 2008 Part 1: overview. Schizophr Res 2008; 100: 4-19.
6. Clish CB, Davidov E, Oresic M, Plasterer TN, Lavine G, Londo T et al. Integrative biological analysis of the APOE*3-leiden transgenic mouse. OMICS 2004; 8: 3-13.
7. Yao JK, Reddy RD. Metabolic investigation in psychiatric disorders. Mol Neurobiol 2005; 31: 193-203.
8. Kaddurah-Daouk R. Metabolic profiling of patients with schizophrenia. PLoS Med 2006; 3: e363.
9. Paige LA, Mitchell MW, Krishnan KR, Kaddurah-Daouk R, Steffens DC. A preliminary metabolomic analysis of older adults with and without depression. Int J Geriatr Psychiatry 2007; 22: 418-423.
10. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM et al. Metabolomic mapping of atypical antipsycho-tic effects in schizophrenia. Mol Psychiatry 2007; 12: 934-945.
11. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 2008; 48: 653-683.
12. Garelis E, Gillin J, Wyatt R, Neff N. Elevated blood serotonin concentration in unmedicated chronic schizophrenic patients. Am J Psychiatry 1975; 132: 184-186.
13. Stahl SM, Wood DJ, Mefford IN, Berger PA, Ciranello RD. Hyperserotoninemia and platelet serotonin uptake and release in schizophrenia and affective disorders. Am J Psychiatry 1983; 140: 26-30.
14. Jackman H, Luchins D, Meltzer HY. Platelet serotonin levels in schizophrenia: relationship to race and psychopathology. Biol Psychiatry 1983; 18: 887-902.
15. Muck-Seler D, Jakovljevie M, Deanovie Z. Time course of schizophrenia and platelet 5-HT level. Biol Psychiatry 1988; 23: 243-251.
16. Joseph M, Owen F, Baker H, Bourne R. Platelet serotonin concentration and monoamine oxidase activity in unmedicated chronic schizophrenic and schizoaffective patients. Psychol Med 1977; 7: 159-162.
17. Kolakowska T, Molyneux SG. Platelet serotonin concentration in schizophrenic patients. Am J Psychiatry 1987; 144: 232-234.
18. Ashcroft GW, Crawford TBB, Eccleston D, Sharman DF, MacDougall EG, Stanton JB et al. 5-Hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological disease. Lancet 1966; 2: 1049-1052.
19. Bowers MB. 5-Hydroxyindole acetic acid (5-HIAA) and homo-vanillic acid (HVA) following protenccid in acute psychiatric patients treated with phenothiazines. Psychopharmacology 1973; 28: 309-318.
20. Manowitz P, Gilmour DG, Racevskis J. Low plasma tryptophan levels in recently hospitalized schizophrenics. Biol Psychiatry 1973; 6: 109-118.
21. Domino EF, Krause RR. Free and bound serum tryptophan in drug-free normal controls and chronic schizophrenic patients. Biol Psychiatry 1974; 8: 265-279.
22. Wyatt RJ, Vaughan T, Galanter M, Kaplan J, Green R. Behavioral changes of chronic schizophrenic patients given L-5-hydroxy-tryptophan. Science 1972; 177: 1124-1126.
23. Gillin JC, Kaplan JA, Wyatt RJ. Clinical effects of tryptophan in chronic schizophrenic patients. Biol Psychiatry 1976; 11: 635-639.
24. Meltzer HY. Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989; 99: S18-S27.
25. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bulletin 1991; 17: 263-287.
26. Schwarcz R, Rassoulpour A, Wu H-Q, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001; 50: 521-530.
27. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998-1007.
28. Yao JK, Cheng P. Determination of multiple redox-active compounds by high-performance liquid chromatography with coulo-metric multi-electrode array system. J Chromatogr B 2004; 810: 93-100.
29. Kristal BS, Shurubor YI, Kaddurah-Daouk R, Matson WR. High-performance liquid chromatography separations coupled with coulometric electrode array detectors: a unique approach to metabolomics. Methods Mol Biol 2007a; 358: 159-174.
30. Shi H, Vigneau-Callahan KE, Matson WR, Kristal BS. Attention to relative response across sequential electrodes improves quantita-tion of coulometric array. Anal Biochem 2002; 302: 239-245.
31. Shi H, Paolucci U, Vigneau-Callahan KE, Milbury PE, Matson WR, Kristal BS. Development of biomarkers based on diet-dependent metabolic serotypes: practical issues in development of expert system-based classification models in metabolomic studies. OMICS 2004; 8: 197-208.
32. Rozen S, Cudkowicz ME, Bogdanov M, Matson WR, Kristal BS, Beecher C et al. Metabolomic analysis and signature in motor neuron disease. Metabolomics 2005; 2: 101-108.
33. Bogdanov MB, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008; 131: 389-396.
34. Schiavo S, Ebbel E, Sharma S, Matson W, Kristal BS, Hersch S et al. Metabolite identification using a nanoelectrospray LC-EC-array integrated system. Anal Chem 2008; 80: 5912-5923.
35. Eriksson L, Johansson E, Kettanah-Wold N, Wold S. Multi-and Megavariate Data Analysis. Umetrics AB: Malmo, Sweden, 2001.
36. Hatzimanikatis V, Li C, Ionita JA, Broadbelt LJ. Metabolic networks: enzyme function and metabolite structure. Curr Opin Struct Biol 2004; 14: 300-306.
37. Lehmann EL. Nonparametrics: Statistical Methods Based on Ranks. Holden and Day: San Francisco, p.20 (Rank Sum test) and p.130 (Signed Ranks Test) 1975.
38. Johnson RA, Wichern DW. Applied Multivariate Statistical Analysis, 4th edn, Prentice Hall: Upper Saddle River, NJ, USA, 1998, pp 193, 222-223.
39. Henze N, Zirkler B. A class of invariant consistent tests for multivariate normality. Commun Statist\Theory Meth 1990; 19: 3595-3617.
40. Schott JR. Testing for complete independence in high dimensions. Biometrika 2005; 92: 951-956.
41. Larntz K, Perlman MD. A simple test for the equality of correlation matrices. In: Gupta SS, Berger JO (eds). Statistical Decision Theory and Related Topics IV, v. 2, Springer: New York, 1988, pp 289-298.
42. Drton M, Perlman MD. Model selection for Gaussian concentration graphs. Biometrika 2004; 91: 591-602.
43. Sidák Z. Rectangular confidence regions for the means of multi-variate normal distributions. J Am Stat Assoc 1967; 62: 626-633.
44. Anderson TW. Introduction to Multivariate Statistical Analysis, 2nd edn, Wiley: New York, NY, USA, 1984, pp 102-155.
45. Kendall M, Gibbons JD. Rank Correlation Methods. Oxford University Press: New York, 1990, pp 60-69.
46. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning. Springer: New York, 2001a, pp 95-105.
47. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning. Springer: New York, 2001b, pp 193-217.
48. Payne IR, Walsh EM, Whittenburg EJR. Relationship of dietary tryptophan and niacin to tryptophan metabolism in schizophrenics and nonschizophrenics. Am J Clin Nutrition 1974; 27: 565-571.
49. Cooper JR, Bloom FE, Roth RH. Serotonin (5-hydroxytryptamine). In: Cooper JR, Bloom FE, Roth RH (eds). The Biochemical Basis of Neurophramacology, 4th edn. Oxford University Press: New York, 1982, pp 223-248.
50. Dubocovich ML, Masana MI. Melatonin receptor signaling. In: Encylopedia of Hormones. Elsevier Science: New York, NY, 2003, pp 638-643.
51. Brown GM, Pulido O, Grota LJ, Niles LP. N-Acetylserotonin in the central nervous system. Prog Neuropsychoparmacol Biol Psychiatry 1984; 8: 475-480.
52. Seithikurippu RP-P, Trakht I, Venkataramanujan S, Spence DW, Maestroni GJM, Zisapel N et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol 2008; 85: 335-353.
53. Skinner DC, Malpaux B. High melatonin concentrations in third ventricular cerebrospinal fluid are not due to galen vein blood recirculating through the choroid plexus. Endocrinology 1999; 140: 4399-4405.
54. Tricoire H, Locatelli A, Chemineau P, Malpaux B. Melatonin enters the cerebrospinal fluid through the pineal recess. Endocrinology 2002; 143: 84-90.
55. Reiter RJ. Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab 2003; 17: 273-285.
56. Ernster I. Lipid peroxidation in biological membranes: mechanisms and implications. In: Yagi K (ed). Active Oxygen Species, Lipid Peroxides, and Antioxidants. CRC Press: Tokyo, Japan, 1993, pp 11-38.
57. Whatley SA, Curti D, Das Gupta F, Ferrier IN, Jones S, Taylor C et al. Superoxide, neuroleptics and the ubiquinone and cyto-chrome b5 reductases in brain and lymphocytes from normals and schizophrenic patients. Mol Psychiatry 1998; 3: 227-237.
58. Yao JK, Reddy RD, Van Kammen DP. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001; 15: 287-310.
59. Mahadik SP, Parikh V, Khan MM. The role of oxidative stress in modulating membrane and phospholipid function in schizophrenia. In: Peet M, Glen I, Horrobin D (eds). Phospholipid Spectrum Disorders in Psychiatry and Neurology. Marius Press: Carnforth, UK, 2003, pp 277-288.
60. Ben-Shachar D, Laifenfeld D. Mitochondria, synaptic plasticity, and schizophrenia. Int Rev Neurobiol 2004; 59: 273-296.
61. Bubber P, Tang J, Haroutunian V, Xu H, Davis KL, Blass JP et al. Mitochondrial enzymes in schizophrenia. J Mol Neurosci 2004; 24: 315-321.
62. Yao JK, Leonard S, Reddy RD. Altered glutathione redox state in schizophrenia. Dis Markers 2006; 22: 83-93.
63. Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P et al. Impaired glutathione synthesis in schizophrenia: Convergent genetic and functional evidence. Proc Natl Acad Sci USA 2007; 104: 16621-16626.
64. Poeggeler B, Reiter RJ, Tan DX, Chen LD, Manchester LC. Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis. J Pineal Res 1993; 14: 151-168.
65. Tan DX, Reiter RJ, Manchester LC, Yan MT, El-Sawi M, Sainz RM et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002; 2: 181-197.
66. Marshall KA, Reiter RJ, Poeggeler B, Aruoma OI, Halliwell B. Evaluation of the antioxidant activity of melatonin in vitro. Free Radic Biol Med 1996; 21: 307-315.
67. Barlow-Walden LR, Reiter RJ, Abe M, Pablos M, Menendez-Pelaez A, Chen LD et al. Melatonin stimulates brain glutathione peroxidase activity. Neurochem Int 1995; 26: 497-502.
68. Urata Y, Honma S, Goto S, Todoroki S, Iida T, Cho S et al. Melatonin induces gamma-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radic Biol Med 1999; 27: 838-847.
69. Antolin I, Rodriguez C, Sainz RM, Mayo JC, Uria H, Kotler ML et al. Neurohormone melatonin prevents cell damage: effect on gene expression for antioxidant enzymes. FA SE B J 1996; 10: 882-890.
70. Longoni B, Pryor WA, Marchiafava P. Inhibition of lipid peroxi-dation by N-acetylserotonin and its role in retinal physiology. Biochem Biophys Res Commun 1997; 233: 778-780.
71. Garcia JJ, Reiter RJ, Guerrero JM, Escames G, Yu BP, Oh CS et al. Melatonin prevents changes in microsomal membrane fluidity during induced lipid peroxidation. FEBS Lett 1997; 408: 297-300.
72. Garcia JJ, Reiter RJ, Karbownik M, Calvo JR, Ortiz GG, Tan DX et al. N-acetylserotonin suppresses hepatic microsomal membrane rigidity associated with lipid peroxidation. Eur J Pharmacol 2001; 428: 169-175.
73. Duell PB, Wheaton DL, Shultz A, Nguyen H. Inhibition of LDL oxidation by melatonin requires supraphysiologic concentrations. Clin. Chem 1998; 44: 1931-1936.
74. Wolfler A, Abuja PM, Schauenstein K, Liebmann PM. N-acetyl-serotonin is a better extra-and intracellular antioxidant than melatonin. FEBS Lett 1999; 449: 206-210.
75. Wang HX, Liu F, Ng TB. Examination of pineal indoles and 6-methoxy-2-benzoxazolinone for antioxidant and antimicro-bialeffects. Comp Biochem Physiol C Toxicol Pharmacol 2001; 130: 379-388.
76. Fagali N, Catala A. The effect of melatonin and structural analogues on the lipid peroxidation of triglycerides enriched in omega-3 polyunsaturated fatty acids. Life Sci 2007; 81: 299-305.
77. Gavazza MB, Català A. Protective effect of N-acetyl-serotonin on the nonenzymatic lipid peroxidation in rat testicular microsomes and mitochondria. J Pineal Res 2004; 37: 153-160.
78. Van Der Heijdena FMMA, Tuiniera S, Fekkesb D, Sijbena AES, Kahnc RS, Verhoevena WMA. Atypical antipsychotics and the relevance of glutamate and serotonin. Eur Neuropsychopharmacol 2004; 14: 259-265.
79. Scheepers FE, Gispen-de Wied CC, Westenberg HGM, Kahn RS. The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Neuropsychopharmacology 2001; 25: 468-475.
80. Sailer CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993; 112: 285-292.
81. Bell C, Abrams J, Nutt D. Tryptophan depletion and its implications for psychiatry. Br J Psychiatry 2001; 178: 399-405.
82. D'Souza D, Gil R, Abi-Draghjam A. Tryptophan depletion paradigm: implications for schizophrenia. Biol Psychiatry 1994; 35: 703.
83. Sharma RP, Shapiro LE, Kamath SK, Soll EA, Watanabe MD, Davis JM. Acute dietary tryptophan depletion: effects on schizophrenic positive and negative symptoms. Neuropsychobiology 1997; 35: 5-10.
84. Golightly K, Lloyd J, Hobson J, Gallagher P, Mercer G, Young AH. Acute tryptophan depletion in schizophrenia. Psychol Med 2001; 31: 75-84.
85. Rawashdeh O, de Borsetti NH, Roman G, Cahill GM. Melatonin suppresses nighttime memory formation in Zebrafish. Science 2007; 318: 1144-1146.
86. Tuckwell HC, Koziol JA. On the concentration of 5-hydroxyindo-leacetic acid in schizophrenia: a meta-analysis. Psychiatry Res 1996; 59: 239-244.
87. Issa F, Gerhardt GA, Bartko JJ, Suddath RL, Lynch M, Gamache PH et al. A multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia: I. Comparisons with healthy control subjects and neuroleptic-treated/unmedicated pairs analyses. Psychiatry Res 1994; 52: 237-249.
88. Stone TW. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 1993; 45: 309-379.
89. Hilmas C, Pereira EFR, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The brain metabolite kynurenic acid inhibits a7 nicotinic receptor activity and increases non-a7 nicotinic receptor expression: physiopathological implications. J Neurosci 2001; 21: 7463-7473.
90. Alkondon M, Pereira EFR, Yu P, Arruda EZ, Almeida LEF, Guidetti P et al. Targeted deletion of the kynurenine aminotransferase II gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via a7 nicotinic receptors in the hippocampus. J Neurosci 2004; 24: 4635-4648.
91. Chess AC, Simoni MK, Alling TE, Bucci DJ. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bulletin 2007; 33: 797-804.
92. Kose F, Weckwerth W, Linke T, Fiehn O. Visualization of plant metabolomic correlation networks using clique-metabolite matrices. Bioinformatics 2001; 17: 1198-1208.
93. Watkins SM. Comprehensive lipid analysis: a powerful meta-nomic tool for predictive and diagnostic medicine. Isr Med Assoc J 2000; 2: 722-724.
94. Bengio Y, Grandvalet Y. No unbiased estimator of the variance of K-fold cross-validation. J Mach Learn Res 2004; 5: 1089-1105.